Levin Capital Strategies L.P. Cuts Stock Holdings in Alpha Tau Medical Ltd. $DRTS

Levin Capital Strategies L.P. decreased its position in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) by 13.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 192,514 shares of the company’s stock after selling 30,000 shares during the quarter. Levin Capital Strategies L.P. owned 0.23% of Alpha Tau Medical worth $601,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, Kovitz Investment Group Partners LLC grew its holdings in shares of Alpha Tau Medical by 601.4% during the first quarter. Kovitz Investment Group Partners LLC now owns 226,320 shares of the company’s stock valued at $568,000 after buying an additional 194,055 shares during the last quarter. 2.65% of the stock is currently owned by institutional investors and hedge funds.

Alpha Tau Medical Stock Down 5.8%

DRTS opened at $3.92 on Tuesday. The company has a quick ratio of 5.81, a current ratio of 10.52 and a debt-to-equity ratio of 0.07. The firm has a 50 day moving average price of $3.93 and a 200-day moving average price of $3.33. Alpha Tau Medical Ltd. has a twelve month low of $2.14 and a twelve month high of $4.69. The stock has a market capitalization of $332.49 million, a price-to-earnings ratio of -8.17 and a beta of 1.06.

Alpha Tau Medical (NASDAQ:DRTS) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). Equities research analysts forecast that Alpha Tau Medical Ltd. will post -0.45 earnings per share for the current year.

Wall Street Analyst Weigh In

DRTS has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Alpha Tau Medical to a “sell” rating in a report on Saturday. Finally, HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Alpha Tau Medical in a report on Wednesday, October 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $9.00.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.